Business Wire

Brand Finance Global 500 2025: Apple Is the Most Valuable Brand in the World, NVIDIA Enters Top Ten

21.1.2025 16:22:00 CET | Business Wire | Press release

Share

Apple is once again the world’s most valuable brand. Brand Finance, the world’s leading brand valuation consultancy, values Apple’s brand at USD574.5 billion, ahead of second-placed Microsoft (USD461 billion).

According to Brand Finance’s research, four out of the five most valuable brands in the world are technology brands:

  1. Apple: brand value of USD574.5 billion, up 11% from 2024
  2. Microsoft: USD461.1 billion, up 35%
  3. Google: USD413.0 billion, up 24%
  4. Amazon: USD356.4 billion, up 15%
  5. Walmart: USD137.2 billion, up 42%

Brand Finance also analysed what brands have grown the most since 2020, plus TikTok – although Brand Finance began valuing the brand in 2022, its 79% growth in four years puts it in the same league as the other high-growth brands.

  1. TikTok/Douyin: USD105.8 billion, up from USD59.0 billion (in 2022)
  2. DraftKings: USD5.1 billion, up from USD18 million
  3. FanDuel: USD7.0 billion, up from USD56 million
  4. NVIDIA: USD87.9 billion, up from USD4.7 billion
  5. AMD: USD11.0 billion, up from USD1.4 billion
  6. Pinduoduo: USD13.0 billion, up from USD2.5 billion
  7. BYD: USD14.0 billion, up from USD3.1 billion
  8. Apple: USD574.5 billion, up from USD140.5 billion
  9. TSMC: USD34.2 billion, up from US8.6 billion
  10. Microsoft: USD461.1 billion, up from USD117.1 billion
  11. Lilly: USD8.0 billion, up from USD2.1 billion

American gambling brands DraftKings and FanDuel are cashing in as online gambling becomes legal in more American states. Semiconductor brands NVIDIA, AMD, and TSMC advance new technologies, while tech giants Apple and Microsoft lead from the front.

David Haigh, Founder & CEO, Brand Finance, commented:

“Our analysis of what brands have grown the most since 2020 reveals that technology companies do not have a monopoly on sustained brand growth. This also reinforces another global trend: how Chinese brands like TikTok, Pinduoduo, and BYD lead the charge by creating value and challenging established brand leaders.”

e& is the world’s fastest growing brand value, posting an eight-fold increase following consolidation of brand architecture.

WeChat is the strongest brand, with a Brand Strength Index score of 95.2/100.

View the full Brand Finance Global 500 2025 report here

See details of Brand Finance’s methodology here, along with frequently asked questions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250121799865/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release

IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye